Across TCGA pan-cancer cohorts, TTC25 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TTC25 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher TTC25 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTC25 expression acts as an unfavorable survival marker.

SARC and PRAD are the cancer types where TTC25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TTC25 tumor-vs-normal RNA expression · all TTC25 data types